[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100279500":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":31,"responsibleParty":47,"collaborators":29,"id":51,"slug":29,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":29,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":29,"maxAge":58,"enrollmentInfo":59,"targetDuration":29,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":29,"overallStatus":34,"whyStopped":29,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Navy General Hospital, Beijing","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Hydrogen","EXPERIMENTAL","Patients will receive hydrogen-rich water (4mL\u002Fkg three times one day, 0.8 ppm)",[13],"Drug: Hydrogen",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Patients will receive hydrogen-rich water orally (500mL three times one day, 0.6mM)",[9],[20],"Hydrogen-rich water",[22],{"name":23,"affiliation":5,"role":24},"Liren Qian, M.D.","STUDY_CHAIR",[26],{"name":23,"role":27,"phone":28,"phoneExt":29,"email":30},"CONTACT","+861066957676",null,"qlr2007@126.com",[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Navy General Hospital","RECRUITING","Beijing","Beijing Municipality","100048","China",{"type":40,"coordinates":41},"Point",[42,43],116.39723,39.9075,{"lat":43,"lon":42},[46],{"name":23,"role":27,"phone":28,"phoneExt":29,"email":30},{"type":48,"investigatorFullName":49,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":29,"oldOrganization":29},"PRINCIPAL_INVESTIGATOR","Liren Qian","Doctor","100279500",false,"NCT02918188","Therapeutic Effects of Hydrogen on Steroid-refractory\u002For Steroid-dependent cGVHD","Therapeutic Effects of Hydrogen on Steroid-refractory\u002For Steroid-dependent Chronic Graft-versus-host-disease","Inclusion Criteria:\n\n* Written informed consent\n* Male\n* not pregnant female\n* patients \\\u003C65 years old\n* Diagnosis of cGVHD steroid refractory (no response after Prednisone ≥1mg\u002Fkg ) or steroid-dependent cGVHD (had an initial response followed by a cGVHD flare upon steroid taper)\n* Patient intolerant to steroid therapy\n\nExclusion Criteria:\n\n* Patients with stable disease, not well controlled by the current treatment\n* Pregnancy\n* HIV positive\n* Severe liver or renal impairment: serum creatinine \\>2.5 mg\u002Fdl; serum bilirubin\\>2.5 mg\u002Fdl (without evidence of hepatic cGVHD)\n* Uncontrolled malignancies including the persistence of the underlying malignancy before the Allogeneic Transplantation and the relapse of hematopoietic malignancy\n* Any other investigational agents administered within last four weeks\n* Cardiac insufficiency (\\>grade II, New York Heart Association classification)\n* Inability to comply with medical therapy or follow-up","ALL","65 Years",{"count":60,"type":61},21,"ESTIMATED","INTERVENTIONAL",[64],"PHASE2","This study suggested that hydrogen has a potential as an effective and safe therapeutic agent on cGVHD.",[67],"Chronic Graft-versus-host Disease","2020-07-17",{"date":70,"type":71},"2020-07-21","ACTUAL",{"date":73,"type":29},"2016-01",{"date":75,"type":61},"2031-01",{"name":5,"class":6},1]